In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2878-2890

  Hemminki, O ^a   Immonen, R ^b   Narvainen J ^b   Kipar, A ^c,d   Paasonen, J ^b   Jokivarsi, K T ^b   Yli Ollila, H ^b,e   Soininen, P ^b   Partanen, K ^f   Joensuu, T ^f   Parvianen, S ^a   Pesonen, S K ^a   Koski, A ^a   Vaha Koskela M ^a   Cerullo, V ^a,g   Pesonen, S ^a   Grohn O H ^b   Hemminki, A ^a,f,h  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f Docrates Oncology Clinic   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h Oncos Therapeutics Ltd   (Finland)

Author keywords

adenovirus; cancer; MRI; MRS; oncolytic

Indexed keywords

CALGRANULIN; CHOLINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS; TAURINE; UNSATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; EX VIVO STUDY; HETEROPHIL; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATORY CELL; LEIOMYOSARCOMA; MACROPHAGE; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; SYRIAN HAMSTER; T LYMPHOCYTE; TUMOR NECROSIS; TUMOR VOLUME;

ADENOVIRUS; CANCER; MRI; MRS; ONCOLYTIC;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CELLS, CULTURED; CHOLINE; CRICETINAE; FATTY ACIDS, UNSATURATED; HUMANS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NECROSIS; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; SARCOMA; TAURINE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84898001762     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28615     Document Type: Article

References (42)

1. Reid TR, Freeman S, Post L, et al. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005; 12: 673-81.
2. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-71.
3. Hemminki O, Diaconu I, Cerullo V, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012; 20: 1821-30.
4. Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-42.
5. Lu W, Zheng S, Li XF, et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004; 10: 3634-8.
6. Pesonen S, Nokisalmi P, Escutenaire S, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010; 17: 892-904.
7. Turunen TMO, Nokisalmi P, Cerullo V, et al. Effect of oncolytic adenovirus on tumor marker levels in cancer patients and in preclinical test systems, ASGCT Meeting Abstracts, 2009.
8. Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19: 1913-22.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
10. Minchom A, Young K, Larkin J,. Ipilimumab: showing survival benefit in metastatic melanoma. Future Oncol 2011; 7: 1255-64.
11. Limanond P, Zimmerman P, Raman SS, et al. Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies. Am J Roentgenol 2003; 181: 1635-40.
12. Braga L, Semelka RC, Pedro MS, et al. Post-treatment malignant liver lesions. MR imaging. Magn Reson Imaging Clin N Am 2002; 10: 53-73.
13. Ozkavukcu E, Haliloglu N, Erden A,. Post-treatment MRI findings of hepatocellular carcinoma. Diagn Interv Radiol 2009; 15: 111-20.
14. Glunde K, Bhujwalla ZM,. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol 2011; 38: 26-41.
15. Begley JK, Redpath TW, Bolan PJ, et al. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res 2012; 14: 207.
16. Srivastava S, Roy R, Singh S, et al. Taurine-a possible fingerprint biomarker in non-muscle invasive bladder cancer: a pilot study by 1H NMR spectroscopy. Cancer Biomark 2010; 6: 11-20.
17. Beckonert O, Monnerjahn J, Bonk U, et al. Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed 2003; 16: 1-11.
18. De Micheli E, Alfieri A, Pinna G, et al. Extracellular levels of taurine in tumoral, peritumoral and normal brain tissue in patients with malignant glioma: an intraoperative microdialysis study. Adv Exp Med Biol 2000; 483: 621-5.
19. Swanson MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003; 50: 944-54.
20. Tessem MB, Selnaes KM, Sjursen W, et al. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res 2010; 9: 3664-70.
21. EL Agouza IMA, EL Nashar DE,. Serum taurine as a marker of endometrial cancer. Open Women's Health J 2011; 5: 1-6.
22. El Agouza IM, Eissa SS, El Houseini MM, et al. Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients. Angiogenesis 2011; 14: 321-30.
23. Liimatainen TJ, Erkkila AT, Valonen P, et al. 1H MR spectroscopic imaging of phospholipase-mediated membrane lipid release in apoptotic rat glioma in vivo. Magn Reson Med 2008; 59: 1232-8.
24. Delikatny EJ, Cooper WA, Brammah S, et al. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002; 62: 1394-400.
25. Cohen AM, Hines DK, Korach ES, et al. In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56: 2861-5.
26. Bortolanza S, Alzuguren P, Bunuales M, et al. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-90.
27. Diaconu I, Cerullo V, Escutenaire S, et al. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. J Gene Med 2010; 12: 435-45.
28. Cho SA, Park JH, Seok SH, et al. Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. Exp Toxicol Pathol 2006; 57: 321-8.
29. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
30. Hakkarainen T, Hemminki A, Curiel DT, et al. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. Int J Mol Med 2006; 18: 751-9.
31. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
32. Lee I, Boucher Y, Jain RK,. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992; 52: 3237-40.
33. Pesonen S, Helin H, Nokisalmi P, et al. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol 2010; 49: 117-19.
34. Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-66.
35. Kipar A, Kohler K, Leukert W, et al. A comparison of lymphatic tissues from cats with spontaneous feline infectious peritonitis (FIP), cats with FIP virus infection but no FIP, and cats with no infection. J Comp Pathol 2001; 125: 182-91.
36. Khajah M, Millen B, Cara DC, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo. J Leukoc Biol 2011; 89: 945-53.
37. Liikanen I, Monsurro V, Ahtiainen L, et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 2011; 19: 1858-66.
38. Papatriantafyllou M,. Cytokines: GM-CSF in focus. Nat Rev Immunol 2011; 11: 370-1.
39. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
40. Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011; 19: 1170-9.
41. Liu HL, Chen J,. Oncolytic virus as an agent for the treatment of malignant ascites. Cancer Biother Radiopharm 2009; 24: 99-102.
42. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-84.